canada semaglutide patent Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Off-patent semaglutide in 2026: the

Bruce Verchere, Andrew N

[DOI] [PMC free article] [PubMed] [Google Scholar] 269.Sharma AE, Willard-Grace R, Hessler D, Bodenheimer T, Thom DH

Over time, the drugs active ingredients may break down, reducing its effectiveness

All clinical decisions regarding semaglutide therapy and monitoring protocols should be made by qualified healthcare providers based on individual patient assessment

Wegovy is FDA approved for chronic weight management in adults and adolescents 12 years and older with obesity or adults with overweight and at least one weight-related medical condition

Spicy meals, creamy sauces and fried foods are common triggers